Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

formulation

formulation is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 135
News articles 0
Drug details — formulation
Class
—
Route
—
Patents
20
Programs
135
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

formulation is an FDA-listed pharmaceutical active ingredient.

Key facts

INN formulation

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 0600-PG-PSC-218 Phase 3 · Anaxis Pharma · Allergic rhinoconjunctivitis with or without controlled asth
  2. 060018-PG-PSC-217 Phase 3 · Anaxis Pharma · Allergic rhinoconjunctivitis with or without asthma due to c
  3. 20190529 Phase 3 · Amgen · Juvenile psoriatic arthritis
  4. 2024/4031 Phase 3 · George Institute for · Patients with primary HPV high-grade squamous intra-epitheli
  5. 230LE301 Phase 3 · Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lu
  6. 230LE303 Phase 3 · Biogen · systemic lupus erythematosus
  7. 230LE304 Phase 3 · Biogen · systemic lupus erythematosus
  8. 230LE306 Phase 3 · Biogen · Systemic lupus erythematosus

Related patents

Browse patents

  1. WO 2026106858

    FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES

    Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026087531

    FORMULATIONS DE CLASCOTÉRONE ET LEURS MÉTHODES D'UTILISATION

    Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 20260108463

    NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION

    Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 20260027049

    AVACOPAN FORMULATIONS

    Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2026008525

    FORMULATIONS STABLES CONTENANT DES RADIONUCLÉIDES

    Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026010917

    FORMULATIONS NUTRITIONNELLES PERMETTANT DE MAINTENIR DES MICROBIOTE ET FONCTION INTESTINAUX SAINS

    Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2025242584

    FORMULATION DE CAPSULE DE GÉLATINE MOLLE STABLE POUR ÉLINZANÉTANT

    Expires Wed Nov 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2025242583

    NOUVELLE FORMULATION COMPRENANT DE L'ÉLINZANÉTANT DANS UNE DISPERSION SOLIDE

    Expires Wed Nov 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12419958

    Clinical formulations

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2025186043

    FORMULATION PHARMACEUTIQUE POUR ANTICORPS ANTI-CCR8

    Expires Thu Sep 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12403164

    Lentiviral vector formulations

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12403183

    Factor VIII polypeptide formulations

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12370241

    Nasal powder formulation for treatment of hypoglycemia

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12370188

    Formulations of dazucorilant, a glucocorticoid receptor modulator

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12364685

    Isoxazoline parasiticide formulations

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12357582

    Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12357604

    Topical formulations of cannabinoids and use thereof in the treatment of pain

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12357623

    Method for treating a disease or condition using a pyrazole compound or formulation thereof

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12343350

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12343324

    Dihydromyricetin hot melt extrusion formulations and methods for forming them

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is formulation?

formulation is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.